170 related articles for article (PubMed ID: 31846627)
1. Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects.
Jiang Y; Jin M; Chen J; Yan J; Liu P; Yao M; Cai W; Pi R
Eur J Pharmacol; 2020 Feb; 868():172871. PubMed ID: 31846627
[TBL] [Abstract][Full Text] [Related]
2. N2L, a novel lipoic acid-niacin dimer, attenuates ferroptosis and decreases lipid peroxidation in HT22 cells.
Peng W; Zhu Z; Yang Y; Hou J; Lu J; Chen C; Liu F; Pi R
Brain Res Bull; 2021 Sep; 174():250-259. PubMed ID: 34171402
[TBL] [Abstract][Full Text] [Related]
3. N2L, a novel lipoic acid-niacin dimer protects HT22 cells against β-amyloid peptide-induced damage through attenuating apoptosis.
Wang R; Zhang L; Liao R; Li Q; Pi R; Yang X
Metab Brain Dis; 2019 Dec; 34(6):1761-1770. PubMed ID: 31478183
[TBL] [Abstract][Full Text] [Related]
4. The mechanism and mitigation of niacin-induced flushing.
Kamanna VS; Ganji SH; Kashyap ML
Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.
Shen HC; Ding FX; Deng Q; Wilsie LC; Krsmanovic ML; Taggart AK; Carballo-Jane E; Ren N; Cai TQ; Wu TJ; Wu KK; Cheng K; Chen Q; Wolff MS; Tong X; Holt TG; Waters MG; Hammond ML; Tata JR; Colletti SL
J Med Chem; 2009 Apr; 52(8):2587-602. PubMed ID: 19309152
[TBL] [Abstract][Full Text] [Related]
6. Nicotinic acid: an old drug with a promising future.
Bodor ET; Offermanns S
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S68-75. PubMed ID: 18037924
[TBL] [Abstract][Full Text] [Related]
7. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB
Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of extended-release niacin with laropiprant.
Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
[TBL] [Abstract][Full Text] [Related]
9. Niacin-a critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular disease.
Mason CM; Doneen AL
J Cardiovasc Nurs; 2012; 27(4):303-16. PubMed ID: 21804401
[TBL] [Abstract][Full Text] [Related]
10. Niacin: the evidence, clinical use, and future directions.
Villines TC; Kim AS; Gore RS; Taylor AJ
Curr Atheroscler Rep; 2012 Feb; 14(1):49-59. PubMed ID: 22037771
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
12. Niacin, an old drug with new perspectives for the management of dyslipidaemia.
Benhalima K; Muls E
Acta Clin Belg; 2010; 65(1):23-8. PubMed ID: 20373594
[TBL] [Abstract][Full Text] [Related]
13. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
Jacobson TA
Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295
[TBL] [Abstract][Full Text] [Related]
14. Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist.
Sprecher D; Maxwell M; Goodman J; White B; Tang CM; Boullay V; de Gouville AC
Eur J Pharmacol; 2015 Jun; 756():1-7. PubMed ID: 25773497
[TBL] [Abstract][Full Text] [Related]
15. Determination of newly synthesized lipoic acid-niacin dimer in rat plasma by UPLC/electrospray ionization tandem mass spectrometry: assay development, validation and application to a pharmacokinetic study.
Chen X; Gao J; Jiang Y; Huang P; Xie Y; Pi R; Zhu S; Yao M
Biomed Chromatogr; 2014 Feb; 28(2):213-7. PubMed ID: 23934776
[TBL] [Abstract][Full Text] [Related]
16. New evidence for nicotinic acid treatment to reduce atherosclerosis.
Montecucco F; Quercioli A; Dallegri F; Viviani GL; Mach F
Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1457-67. PubMed ID: 20936932
[TBL] [Abstract][Full Text] [Related]
17. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
[TBL] [Abstract][Full Text] [Related]
18. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
Olsson AG
Expert Opin Pharmacother; 2010 Jul; 11(10):1715-26. PubMed ID: 20518616
[TBL] [Abstract][Full Text] [Related]
19. Novel Niacin Receptor Agonists: A Promising Strategy for the Treatment of Dyslipidemia.
Kothawade PB; Thomas AB; Chitlange SS
Mini Rev Med Chem; 2021; 21(17):2481-2496. PubMed ID: 33550969
[TBL] [Abstract][Full Text] [Related]
20. The role of niacin in lipid-lowering treatment: are we aiming too high?
Gouni-Berthold I; Berthold HK
Curr Pharm Des; 2013; 19(17):3094-106. PubMed ID: 23317400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
